Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS: +63.2%
Free cash flow: −112.8%

Quarter to June 2026, against a year earlier

Insider buying

16.01 1.82 +12.83%

Follow SMMT

Alert me

Market cap: $11.3B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.88
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Summit Therapeutics PLC 10-Q filed Oct 30, 2024

Fiscal Q3 2024 · Period ended Sep 30, 2024 · Filed Oct 30, 2024 · accepted 7:33 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov